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CytoskeletonHypoxia inducible factor-1 (HIF-1), a dimeric transcription factor of the bHLH-PAS family, is comprised of
HIF-1α, which is inducible by hypoxia and ARNT or HIF-1β, which is constitutively expressed. HIF-1 is involved
in cellular homeostasis under hypoxia, in development and in several diseases affected by oxygen availability,
particularly cancer. Since its expression is positively correlatedwith poor outcome prognosis for cancer patients,
HIF-1 is a target for pharmaceutical therapy.We have previously shown that male germ cell Rac GTPase activat-
ing protein (MgcRacGAP), a regulator of Rho proteinswhich are principally involved in cytoskeletal organization,
binds to HIF-1α and inhibits its transcriptional activity. In this work, we have explored the mechanism of the
MgcRacGAP-mediatedHIF-1 inactivation.We show that theMyo domain ofMgcRacGAP,which is both necessary
and sufﬁcient for HIF-1 repression, binds to the PAS-B domain of HIF-1α. Furthermore MgcRacGAP competes
with ARNT for binding to the HIF-1α PAS-B domain, as shown by in vitro binding pull down assays. In mamma-
lian cells, ARNT overexpression can overcome the MgcRacGAP-mediated inhibition and MgcRacGAP binding to
HIF-1α in vivo inhibits its dimerization with ARNT. We additionally present results indicating that MgcRacGAP
binding to HIF-1α is speciﬁc, since it does not affect the transcriptional activity of HIF-2, a close evolutionary
relative of HIF-1 also involved in hypoxia regulation and cancer. Our results reveal a new mechanism for HIF-1
transcriptional activity regulation, suggest a novel hypoxia-cytoskeleton link and provide new tools for selective
HIF-1 inhibition.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
HIF-1 is a transcriptional activator that regulates the transcription of
several hundreds of genes. Changes in the transcriptional activity of
HIF-1 target genes promote survival of cells under low oxygen tension
(hypoxia) or other stimuli. HIF-1 acts in all mammalian cells, in adult
as well as in embryonic organisms under physiological or pathological
conditions. It is a heterodimer comprising the inducible regulatory
HIF-1α subunit and the constitutively expressed aryl hydrocarbon
receptor nuclear translocator (ARNT) subunit, both members of theNT, aryl hydrocarbon receptor
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l rights reserved.basic helix–loop–helix (bHLH) Per-ARNT-Sim (PAS) family of transcrip-
tion factors [1]. This family is characterized by the presence of the PAS
dimerization domain that contains two conserved core repeats, PAS-A
and PAS-B [2]. HIF-1α is induced by hypoxia through an oxygen
dependent post-transcriptional mechanism: under normoxia, HIF-1α
is continuously degraded by the proteasome because its oxygen depen-
dent degradation (ODD) domain is hydroxylated on two prolines, as the
result of oxygen availability (used as a substrate in the hydroxylation
reaction) [3,4]. Degradation is mediated by interaction of the hydroxyl-
ated domain of HIF-1α with the von Hippel–Lindau protein (pVHL), a
constituent of an E3 ubiquitin ligase complex [5]. When O2 levels
drop, the prolyl hydroxylases (PHDs) responsible for HIF-1α hydroxyl-
ation are inactive, HIF-1α is stabilized, rapidly accumulates in the
nucleus, heterodimerizes with ARNT via the PAS domain and the
heterodimer binds to hypoxia responsive elements (HREs) residing on
the promoters of its target genes, altering the transcriptome of the cell
according to the stimulus that induced HIF-1α. The non-inducible
subunit, ARNT, heterodimerizes nοt only with HIF-1α and HIF-2α but
also with aryl hydrocarbon receptor (AhR) and other molecules such
as estrogen receptor (ER) α and β [6], Rel/B, CD30 [7] playing a role
in responses such as xenobiotic metabolism, immune response
and diabetes [8]. HIF-1α expression and activity are additionally
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under normoxic conditions by signals that affect major cellular path-
ways such as those involving PI3K/AKT or MAPK/ERK, both of which
can be stimulated by growth factors, cytokines, metabolic signals, reac-
tive oxygen species (ROS), oncogenes, or hypoxia-mimetic chemicals
[9,10]. HIF-2α, α protein 48% identical to HIF-1α, but less studied, also
participates to the cellular response to hypoxia being globally regulated
similarly to HIF-1α. However, there are several aspects that differenti-
ate between the two paralogues in tissue speciﬁcity, regulation, target
gene speciﬁcity and participation in tumoral growth [11].
The cause of HIF activation, hypoxia and/or deregulation of signal-
ing pathways is often observed in cancer cells. Intratumoral hypoxia,
loss-of-function of tumor-suppressor genes and gain of function of
oncogenes and viral transforming genes, induce HIF-1α. Levels of
HIF-1α correlate with tumor growth, vascularization and metastasis
both in animal models and in clinical studies. Induction of HIF-1α
leads to stimulation of angiogenesis and metabolic reprogramming
of cancer cells, promoting their proliferation, migration, metastasis
and resistance to therapy [12]. HIF-1 is, therefore, an established val-
idated therapeutic target in anti-cancer treatment. Many anticancer
drugs have been shown to inhibit HIF-1α activity and many antican-
cer efforts are aimed at discovering new and selective inhibitors of
HIF-1α activity [13,14].
In a previous study we have used the yeast two hybrid system to
identify interacting proteins with the central part of HIF-1α
(aminoacids 244–532). This region encompasses most of the PAS-B
domain and the region preceding the N-TAD domain. We have fo-
cused our study to the interacting protein MgcRacGAP that as we
have demonstrated, binds to HIF-1α via its N-terminal region
(aa 1–138) containing the Myo (myosin like coiled-coil) domain of
the protein (aa 41–124) [15].
MgcRacGAP belongs to the family of GTPase activating proteins
(GAPs) which interact with the GTP-bound small G proteins of the
Rho family and stimulate GTP hydrolysis. Thus, they negatively
regulate the function of Rho proteins, accelerating transition to their
inactive GDP-bound form. RhoA, Rac1 and Cdc42, the prototypes of
the Rho family GTPases, regulate signaling pathways that control cyto-
skeletal organization [16]. MgcRacGAP has speciﬁcity for Rac1 and
Cdc42 [17,18] and when phosphorylated at Ser387 during mitosis by
Aurora B kinase, it changes speciﬁcity, being inactive versus Rac1,
but active towards RhoA [19]. It contains three functional domains:
the coiled coil myosin-like domain residing at the N-terminus, the
PKC-like cysteine rich domain and the catalytic domain, responsible
for its GAP activity. MgcRacGAP plays different roles in interphase
cells and in mitotic cells. During interphase it inactivates Rac1, in-
volved in the formation of lamellipodia and the activation of NADPH
oxidase, whereas duringmitosis it is required for cytokinesis as a scaf-
folding factor and/or a RhoA GAP. In fact, requirement or dispensabil-
ity of its catalytic activity for cytokinesis have both been reported for
different cell lines [20,21] and it seems indeed that RhoA activation
requirement for cytokinesis is cell type speciﬁc [22]. However, the
requirement of MgcRacGAP for normal cytokinesis for all types of
cells underlines its essential function as a scaffold protein for cytokine-
sis effectors. Finally, new roles of MgcRacGAP have emerged the last
few years, such as its chaperone function for the nuclear translocation
of the transcription factor STAT3 [23] and its involvement in v-src
induced transformation of NIH3T3 cells [24]. The HIF-1α binding
domain of MgcRacGAP (Myo) is not involved in Rac1 binding or
STAT3 activation and transport. It has however been shown to be nec-
essary for MgcRacGAP function during cytokinesis. It binds tubulins
[25], Ect2, a RhoA GEF [26] and, to the 40 N-terminal domain amino
acids preceding it, binds the kinesin MKLP1 [27].
In the present study we unravel the mechanism by which
MgcRacGAP represses HIF-1 function: it associates with the PAS-B
domain of HIF-1α and displaces ARNT, thereby reducing the tran-
scriptionally active HIF-1α-ARNT heterodimers.2. Materials and methods
2.1. Plasmid constructions
pBEVY-GU-GFP-MgcRacGAP(1–138) was constructed by PCR am-
pliﬁcation of MgcRacGAP(1–138) and cloned into the BamHI site of
pBEVY-GU-GFP [28] using the following primers:
sense 5′-ΤΤΤΤΤGGATCCATGGATACTATGATGCTGA-3′
antisense 5′-TTTTTGGATCCTTAATTGCTGCTGGATGG-3′, (BamHI sites
are underlined).
pHisGFP-HIF-1α(240–353) was constructed by PCR ampliﬁcation
of HIF-1α(240–353) and cloned into the BamHI site of pHisGFP
[29] using the following primers:
sense 5′-TTTTGGATCCAAGACTTTCCTCAGTCG-3′
antisense 5′-TTTTGGATCCGAGAAAATCAAGTCGTGCT-3′, (BamHI sites
are underlined). Similarly, pHisGFP-HIF-1α(336–529) was constructed
by PCR ampliﬁcation of HIF-1α(336–529) and cloned into the BamHI
site of pHisGFP using the following primers:
sense 5′-TTTTGGATCCGTATGTGTGAATTACGTTGTG-3′
antisense 5′-TTTTGGATCCATTGACCATATCACTATCC-3′, (BamHI sites
are underlined).
pFLAG-ARNT was constructed by subcloning the BamHI fragment of
full length human ARNT from pET-GST-ARNT [29] in pFLAG-CMV-2
(Sigma).
The pAC28-ARNT-bHLH-PAS, a bacterial expression plasmid that
codes for the amino terminal part of human ARNT (amino acids
1–474), in fusion to a thioredoxine six histidine (TrxH6) epitope [30]
was kindly provided byMurray L.Whitelaw (Discipline of Biochemistry,
University of Adelaide, Australia).
The following plasmidswere previously reported: pARNT-HIF-1α and
pHRElacZ [31], pGEX-HIF-1α(1–530) [32], pHisGFP-HIF-1α(244–532)
and pGEX-4T1-MgcRacGAP(1–138) [15], pEGFP-HIF-1α [33], pEGFP-
HIF-2α [34], pME18S-FLAG-MgcRacGAP, pME18S-FLAG-ΔMyo-
MgcRacGAP, pME18S-FLAG-R386A*MgcRacGAP [25].
The ﬁreﬂy luciferase pGL3-5HRE-VEGF plasmid was kindly provided
by Dr. A. J. Giacia (Stanford University, U.S.A), the pGL3-Sod2 and pGL3-
PGK plasmidswere kindly provided byDr. Joseph A. Garcia (Department
of Medicine, University of Texas Southwestern Medical Center, Dallas)
and Dr. Celeste Simon (Abramson Family Cancer Research Institute,
Philadelphia), respectively. The pCI-Renilla luciferase plasmid was a
gift by Dr. M. U. Muckenthaler (University of Heidelberg, Germany).
2.2. Cell cultures and transfections
Human HeLa, HEK293T or Huh7 cells were cultured in Dulbecco's
modiﬁed Eagle's medium (DMEM, Gibco UK) containing 10% fetal
bovine serum (FBS, Gibco UK) and 100 U/ml penicillin–streptomycin
(Euroclone, UK). Cells were maintained at 37 °C in a 5% CO2/95% air
incubator. For hypoxic exposure, cells were incubated for 4 hours in
1% O2/5% CO2/94% N2 in an IN VIVO2 200 hypoxia work-station
(Ruskinn, Life Sciences). Transient transfections were carried out as
already described [15].
2.3. SDS–PAGE and Western blot
Protein samples were resolved by 8% SDS–PAGE and analyzed by
Coomassie Blue, Silver Staining or Western blotting using a rabbit
anti-HIF-1α polyclonal antibody [15] or a rabbit anti-GFP polyclonal an-
tibody generously provided by Dr. H. Boleti (Hellenic Pasteur Institute,
Athens, Greece) or a mouse anti-ARNT monoclonal antibody (BD
Trasduction Laboratories) or a mouse anti-pentaHis-HRP-conjugated
antibody (Qiagen) or a goat anti-GST polyclonal antibody (Amersham)
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RacGAP1 polyclonal antibody (Santa Cruz Biotechnology) or a mouse
anti-tubulinmonoclonal antibody (Millipore, Billerica,MA, USA).Mem-
branes were then incubated with horseradish peroxidase-conjugated
goat anti-mouse or mouse anti-goat or goat anti-rabbit IgG antibody
(all from Cell Signalling) followed by ECL. Visualization was performed
by developing the signal on ﬁlm or by using a transilluminator (UVItec
Alliance 4.7., Cambridge, UK).
2.4. Protein expression and puriﬁcation
The expression and puriﬁcation of GST-fusion and His-tagged pro-
teins were carried out as already described [15], with minor modiﬁca-
tions. In buffers A and B, 5 μΜ pepstatin and 1 μM aprotinin were
used instead of EDTA-free protease inhibitors (all from Sigma). Buffer
B was adjusted to: 25 mM Tris-Cl pH 7.4, 150 mM NaCl, 2 mMMgCl2,
1 mM PMSF and 1% Triton X-100. The quantity of isolated GST-fusion
or His-tagged proteins was assessed by SDS–PAGE followed by
Coomassie Blue or silver staining or detection with the relevant anti-
bodies by western blotting.
2.5. In vitro binding assays
Approximately 15 μg of puriﬁed GST or GST-MgcRacGAP(1–138)
were immobilized on 25 μl of glutathione-sepharose beads (Amersham)
and incubated with 25 μg of puriﬁed His-GFP-HIF-1α(244–532), His-
GFP-HIF-1α(240–353) or His-GFP-HIF-1α(336–529) for 4 hours at
4 °C in buffer B. At the end of the incubation the beads were washed
three times in ice cold buffer B and bound proteins were eluted in 1×
SDS–PAGE loading buffer. Samples were analyzed by SDS–PAGE and
Western blotting using the relevant antibodies.
2.6. Immunoprecipitation
Huh7 or HEK293T cells grown in 10 cm culture dishes were
transfected with equal quantities of plasmids or subjected to 1% O2
for 4 hours when needed. Twenty four hours post-transfection the
cells were washed with cold buffer PBS and lysed in ice cold buffer
C containing 25 mM HEPES pH 7.6, 150 mM NaCl, 2 mM MgCl2,
1 mM PMSF, 5 mM DTT, 1% Triton X-100, 5 μΜ pepstatin, 1 μΜ
aprotinin (10 min at 4 °C). The cell suspension was centrifuged at
12.000 g for 15 min at 4 °C and the volume of the supernatant was
adjusted to 0.7 ml with buffer C. Samples were incubated with 1 μg
of polyclonal anti-HIF-1α or anti-GFP antibody for 3 hours at 4 °C
under gentle shaking. Twenty microliters of protein-A bead slurry
was added and the incubation continued for 16 hours under the
same conditions. After the incubation, beads were collected by centri-
fugation, washed three times with buffer C and bound proteins were
eluted in 1× SDS–PAGE loading buffer. Samples were analyzed by
SDS–PAGE and Western blotting using the relevant antibodies.
2.7. In vitro competitive binding assays
Approximately 5 μg of puriﬁed GST-HIF-1α(1–530) was incubated
with 0 (only buffer C) or 2.5 or 5 or 10 μg of puriﬁed His-
ARNT(1–474) and 5 μg of puriﬁed GST-MgcRacGAP(1–138) in
0.7 ml of buffer C for 2 hours at 4 °C under gentle shaking. Anti-HIF-
1α polyclonal antibody (1 μg) was added and the incubation continued
for 3 hours under the same conditions. Subsequently, 20 μl of protein-A
bead slurry was added and the incubation continued for 3 more hours
under the same conditions. At the end of the incubation, the samples
were centrifuged, beads were collected and washed three times with
buffer C.
Bound proteins were eluted in 1× SDS–PAGE loading buffer and
were analyzed by SDS–PAGE and silver staining or Western blotting
using the relevant antibodies.For the reverse experiment, 5 μg of puriﬁed GST-HIF-1α(1–530)
was incubated with 0 (only buffer C) or 2.5 or 5 or 10 μg of puriﬁed
GST-MgcRacGAP(1–138) and 5 μg of puriﬁed His-ARNT(1–474) in
0.7 ml of buffer C under the same conditions and incubation time,
following the same analysis.
2.8. Luciferase assays
Huh7 (or HeLa or HEK293T) cells were co-transfected with 0.4 μg
of each plasmid described in the text, with the pCI Renilla plasmid
(0.25 μg per well) and the pGL3-5HRE-VEGF plasmid (0.75 μg per
well) was used in all assays except when, pGL3-PGK or pGL3-Sod2
plasmids (0.75 μg per well) were used as described. Transfected
cells were cultured in 12-well plates for 24 hours or for 20 hours
and subsequently incubated for 4 hours in hypoxia (1% O2). Lucifer-
ase activity was determined in the cell extracts using a dual luciferase
chemiluminescence assay kit (Promega U.S.A) in a luminometer
(TD20/20 Turner Designs).
2.9. Yeast transformation and β-galactosidase assays
Yeast strain RS453 carrying the reporter plasmid pHRE-lacZ and
expressing human ARNT and HIF-1α was transformed with pBEVY-
GU derived plasmids. Independent transformants were selected, cul-
tured and assayed at certain time points for β-galactosidase, as previ-
ously described [31].
2.10. Statistical analysis
Results are expressed as mean ± S.E. Statistical analysis was
assessed using the unpaired t-test in the OpenOfﬁce.org version 3.0 Soft-
ware (Oracle); p b 0.05 was considered to be signiﬁcant (*p b 0.05;
**p b 0.01; ***p b 0.001).
3. Results
3.1. Inhibition of HIF-1 by MgcRacGAP involves its Myo domain but not
its catalytic activity
We have shown previously that the Myo domain of MgcRacGAP is
necessary for HIF-1 transcriptional inhibition since, when deleted, inhi-
bition is abolished [15]. Since, however, MgcRacGAP is a GTPase activat-
ing protein functioning in both interphase and mitosis, we asked if its
catalytic activity is needed for HIF-1 inhibition. We used a mutant form
of MgcRacGAP lacking catalytic activity (FLAG-R386A*MgcRacGAP)
[18]. HeLa cells were transfected with vectors expressing the wild
type FLAG-MgcRacGAP, FLAG-ΔMyo-MgcRacGAP, or FLAG-R386A*
MgcRacGAP and transcriptional activity of hypoxia induced HIF was
measured. As shown in Fig. 1A, FLAG-MgcRacGAP represses HIF-1 (as
previously shown) and themutant FLAG-R386A*MgcRacGAP also re-
presses HIF-1 at practically the same extend, demonstrating that the
catalytic activity of MgcRacGAP is not required for transcriptional
repression of HIF-1. The mutant form of MgcRacGAP lacking the re-
gion containing the Myo domain (FLAG-ΔMyo-MgcRacGAP) was un-
able to inhibit HIF-1 induction under the same conditions, although
FLAG-ΔMyo-MgcRacGAP was efﬁciently expressed, compared to
the protein levels of the different MgcRacGAP isoforms both in
normoxia (Fig. 1B left panel) and under endogenous HIF-1α expres-
sion (Fig. 1B right panel). Once more, our results conﬁrm the neces-
sity of the presence of the Myo region for HIF-1 transcriptional
repression by MgcRacGAP. We further sought to verify that the
Myo domain can independently repress HIF-1 activity so we
subcloned the MgcRacGAP cDNA encoding the Myo domain (amino
acids 1–138) in mammalian expression vectors in order to express
the Myo region of MgcRacGAP in human cells (GFP-Myo, FLAG-Myo
or Myo). In all cases, peptides would create large aggregates
Fig. 1. The Myo domain of MgcRacGAP is sufﬁcient for HIF-1 transcriptional activity repression. (A) HIF-1 transcriptional activity was determined 24 hours after transfection of HeLa
cells with plasmids expressing the indicated proteins. Incubation under hypoxia was for 4 hours. Values are presented as a ratio of ﬁreﬂy over renilla luciferase activity divided by
the value obtained from cells transfected with the empty vector andmaintained in normoxia. Results represent the mean of three independent experiments performed in triplicates
(±S.E.). (B) Western blot analysis of whole cell extracts of HeLa cells transfected with the plasmids expressing the indicated proteins under normoxia (left panel) and hypoxia
(right panel), revealed with the indicated antibodies (C) HIF-1 activity determination in the yeast HIF-1 reconstitution system (see text). Yeast cells were transformed either
with pBEVY-GU-GFP or pBEVY-GU-GFP-MgcRacGAP(1–138) and independent transformants were selected, cultured and aliquots expressing the indicated proteins were analyzed
at the indicated time points for β-galactosidase activity. Culture growth was monitored by OD600 measuring at the speciﬁed time points. Results are shown as average of absolute
values and represent the mean of the results obtained from three independent transformants performed in triplicates.
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bymicroscope examination (data not shown). Wemanaged to circum-
vent this problem by expressing inducibly the GFP-MgcRacGAP(1–138)
peptide in a simple in vivo reconstituted HIF-1 system in yeast: the
HIF-1α and ARNT subunits are expressed in Saccharomyces cerevisiae
under the control of the same bidirectional inducible promoter
and the E scherichia coli β-galactosidase gene expression is under the
control of HREs. This way β-galactosidase quantity produced by yeast
cells reﬂects HIF-1 activity [31]. As shown in Fig. 1C, when GFP-
MgcRacGAP(1–138) was expressed in the yeast HIF-1 reconstitution
system under the control of the same inducible promoter as the HIF-1
subunits, HIF-1 induction was inhibited. The inhibition was evident as
soon as HIF-1 induction was detectable (3 hours of culture) and by
8 hours of culture it attained more than 50%. Yeast culture growth
rates were unaffected by the presence of MgcRacGAP (Fig. 1C). We
repeated the experiment expressing the Myo region of MgcRacGAP in
fusion with GST (GST-MgcRacGAP(1–138)) and obtained practically
the same results (data not shown). We thus can conclude that the
region of MgcRacGAP encompassing amino acids 1–138 is sufﬁcient
for repression of HIF-1 transcriptional activity in the yeast HIF-1 recon-
stitution system.
3.2. MgcRacGAP(1–138) binds in vitro speciﬁcally to the PAS-B domain
of HIF-1α
The region of HIF-1α interaction with MgcRacGAP (aminoacids
244–532) encompasses almost the whole PAS-B domain, responsible
for HIF-1α-ARNT dimerization. Since the PAS-B domain of HIF-1α ex-
tends up to amino acid 343, we constructed two separate peptides
covering the region in question in fusion with GFP (HisGFP-HIF-1α(240–353) and HisGFP-HIF-1α(336–529)) (Fig. 2A) and tested
their binding on the Myo region of MgcRacGAP by in vitro pull
down experiments. As shown in Fig. 2B, HisGFP-HIF-1α(240–353),
encompassing the PAS-B domain, binds to the MgcRacGAP Myo
domain with practically the same efﬁciency as the original HisGFP-
HIF-1α(244–532), whereas HisGFP-HIF-1α(336–529) binds only
weakly. These results show that MgcRacGAP binds to HIF-1α pre-
dominantly via the PAS-B domain, suggesting that it may interfere
with HIF-1α-ARNT heterodimerization.
3.3. MgcRacGAP-mediated HIF-1 transcriptional activity inhibition is
impaired by ARNT overexpression
In order to study the involvement of the constitutively expressed
subunit of HIF-1, ARNT, in the repression of HIF-1 activity by
MgcRacGAP, we examined the expression of HIF-1α in Huh7 human
hepatoma cells in the presence of overexpressed ARNT. HIF-1 expres-
sion was achieved either by overexpressing HIF-1α (transfection with
pEGFP-HIF-1α), or by inducing HIF-1α under low O2 (1%). More spe-
ciﬁcally, cells transfected with pEGFP-HIF-1α in the presence of
pFLAG-MgcRacGAP were co-transfected with pFLAG-ARNT and HIF-1
transcriptional activity was measured. As shown in the left panel of
Fig. 3A, whereas HIF-1 activity is repressed to ~60% in the presence of
pFLAG-MgcRacGAP (see also Ref. [15]), co-transfection with pFLAG-
ARNT restores HIF-1 activity to practically initial levels. GFP-HIF-1α
shows equal expression levels under all conditions and MgcRacGAP
expression levels remain unaffected by FLAG-ARNT overexpression
(Fig. 3A right panel). Accordingly, when endogenous HIF-1 activity
was measured under hypoxia (Fig. 3B, left panel), cells transfected
with pFLAG-ARNT in the presence of pFLAG-MgcRacGAP had a
Fig. 2.MgcRacGAP(1–138) binds in vitro to the PASB domain of HIF-1α. (A) Schematic representation of the HIF-1 fragments used for the in vitro binding assays. Aβ–Ιβ indicate the
corresponding β-strands of the PAS-B domain. The horizontal line corresponds to the fragment used in the two hybrid assay. (B) In vitro binding assay of the HisGFP-
HIF-1α(244–532) (lanes 1, 2, 3), HisGFP-HIF-1α(240–353) (lanes 4, 5, 6) or HisGFP-HIF-1α(336–529) (lanes 7, 8, 9) protein with GST (lanes 2, 5, 8) and GST-
MgcRacGAP(1–138) (lanes 3, 6, 9) followed by western blot with the anti-GFP (upper panel) and anti-GST (lower panel) antibodies. Input (lanes 1, 4, 7) was 1/10 of the quantity
of each one of the HisGFP-HIF-1α peptides used for the assay.
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with only pFLAG-MgcRacGAP. Again, MgcRacGAP protein levels remain
unaffected by FLAG-ARNT overexpression (Fig. 3B, right panel). These
results suggest that theMgcRacGAP-mediated repression of HIF-1 tran-
scriptional activity involves ARNT.3.4. MgcRacGAP competes with ARNT for HIF-1α binding in vitro
According to the data showing that 1) MgcRacGAP binds to HIF-1α
via the PAS-B domain and that 2) the MgcRacGAP mediated repression
of HIF-1 transcriptional activity involves ARNT, we hypothesized that
MgcRacGAP binding to HIF-1α excludes ARNT from dimerizing with
HIF-1α. We thus performed in vitro competition assays between
bacterially produced GST-HIF-1α (1–530), His-ARNT(1–474) and GST-
MgcRacGAP (1–138) (Fig. 4A). GST-HIF-1α (1–530)was either incubat-
ed with equal amounts of MgcRacGAP (1–138) in the presence of
increasing quantities of His-ARNT(1–474), or, inversely, with His-
ARNT(1–474) and increasing quantities of MgcRacGAP (1–138). Subse-
quently, HIF-1α was immunoprecipitated with an anti-HIF-1α poly-
clonal antibody and bound ARNT or MgcRacGAP were detected in the
immunoprecipitates by Western blot, using the relevant antibodies. As
shown in Fig. 4B, both ARNT and MgcRacGAP co-immunoprecipitate
with HIF-1α under the conditions used, in the absence of MgcRacGAP
or ARNT, respectively (lanes 1, 2). When, however, increasing quanti-
ties of ARNT are added to the HIF-1α-MgcRacGAP incubation mixture,
less MgcRacGAP co-immunoprecipitates with HIF-1α and this decrease
inversely correlates with the increase of ARNT amounts (lanes 3–5).
Accordingly, in the reverse experiment, where increasing amounts of
MgcRacGAP are added in the HIF-1α-ARNT incubation mixture, the
amount of ARNT bound to HIF-1α decreases according to MgcRacGAPquantity increase (lanes 6–8). These results show that MgcRacGAP
binding to HIF-1α interferes with HIF-1α-ARNT dimerization.
3.5. In vivo overexpression of MgcRacGAP displaces ARNT from
HIF-1α-ARNT dimers
In order to conﬁrm that MgcRacGAP competes with ARNT for
HIF-1α binding in vivo, we examined the presence of ARNT and
MgcRacGAP in HIF-1α complexes immunoprecipitated from human
cells. HIF-1α was expressed exogenously in normoxia, or induced
under hypoxic conditions in Huh7 cells, in the presence or absence
of MgcRacGAP. As shown in Fig. 5, immunoprecipitates of HIF-1α ei-
ther with the anti-GFP antibody (overexpressed HIF-1α) or the
anti-HIF-1α antibody (HIF-1α expressed under hypoxia) contained
signiﬁcantly lower quantities of ARNT when MgcRacGAP was co-
expressed. More speciﬁcally, in cells exogenously expressing GFP-
HIF-1α, the amount of ARNT that co-immunoprecipitates with
HIF-1α is clearly decreased when MgcRacGAP is present (Fig. 5A,
compare lanes 5 and 6). Accordingly, immunoprecipitates of HIF-1α
from cells subjected to hypoxia contain signiﬁcantly less ARNT
when MgcRacGAP is present (Fig. 5B, compare lanes 3 and 4). Inter-
estingly, as indicated by the results in lanes 2 and 6, endogenous
MgcRacGAP co-immunoprecipitates with HIF-1α.These results show
that MgcRacGAP binding to HIF-1α decreases the amount of HIF-1α
molecules found in dimers with ARNT.
3.6. MgcRacGAP overexpression does not affect HIF-2 transcriptional
activity
The PAS-B domain is one of the most conserved between HIF-1α
and HIF-2α (74.5% identity and 87.3% similarity). In an effort to obtain
Fig. 3.MgcRacGAP mediated HIF-1 transcriptional inhibition is impaired by ARNT overexpression. (A) HIF-1 transcriptional activity was determined 24 hours after transfection (left
panel). Huh7 cells were transfected with plasmids expressing either GFP (black bars) or GFP-HIF-1α (grey bars) and plasmids expressing the indicated proteins. Values are
presented as the ratio of ﬁreﬂy over renilla luciferase activity divided by the value obtained by cells transfected only with the empty vectors. Results represent the mean of
three independent experiments performed in triplicates (±S.E.). Expression levels of GFP-HIF-1α (lanes 1 to 4), FLAG-MgcRacGAP (lanes 3, 4), and FLAG-ARNT (lanes 2, 4),
were monitored by Western blot analysis with the indicated antibodies (right panel). (B) HIF-1 transcriptional activity was determined 24 hours after transfection of Huh7 cells
with plasmids expressing the indicated proteins (left panel). Incubation under hypoxia was for 4 hours. Values are presented as a ratio of ﬁreﬂy over renilla luciferase activity
divided by the value obtained from cells transfected with the empty vector and maintained in normoxia. Results represent the mean of three independent experiments performed
in triplicates (±S.E.). Expression levels of endogenous HIF-1α (lanes 1 to 4), FLAG-MgcRacGAP (lanes 3, 4), and FLAG-ARNT (lanes 2, 4), were monitored by Western blot analysis
with the indicated antibodies (right panel). Statistical comparisons between two groups of data in luciferase assays are indicated with horizontal lines. Asterisk denotes statistical
signiﬁcance. Only values p b 0.05 are considered signiﬁcant (*p b 0.05; **p b 0.01; ***p b 0.001). n.s.: not signiﬁcant.
Fig. 4. MgcRacGAP(1–138) competes with bacterially expressed ARNT and vice versa, on HIF-1α in vitro binding. (A) Silver staining (left panel) and western blot analysis (right
panel) of bacterially expressed and puriﬁed GST-HIF-1α(1–530) (lanes 1, 4), His-ARNT(1–474) (lanes 2, 5) and GST-MgcRacGAP(1–138) (lanes 3, 6) with the indicated antibodies.
Input quantity was 5 μg for each protein. Asterisk denotes the full-length bacterially expressed protein. (B) In vitro competitive binding assay, using anti-HIF-1α antibody for the
immunoprecipitation of 5 μg of puriﬁed GST-HIF-1α(1–530) (upper panel, lanes 1 to 8), pre-incubated with 0 (only buffer), 2.5, 5, 10 μg of His-ARNT(1–474) and 5 μg
GST-MgcRacGAP(1–138) (lanes 2 to 5) or 0, 2.5, 5, 10 μg of GST-MgcRacGAP(1–138) and 5 μg of His-ARNT(1–474) (lanes 1, 6, 7, 8). Anti-GST and anti-His antibodies were used
for the detection of the recombinant proteins, as indicated. Only the relevant parts of the blots are shown.
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Fig. 5. Overexpression of MgcRacGAP prevents ARNT from dimerizing with HIF-1α.
(A) Western blot analysis of inputs (left panels) and immunoprecipitates (right panels)
obtained from HEK293T cells transfected with plasmids encoding GFP (lanes 1, 4) or
GFP-HIF-1α (lanes 2, 3, 5, 6,), FLAG (lanes 2, 5), or FLAG-MgcRacGAP (lanes 1, 3, 4, 6).
Anti-GFP antibody was used for immunoprecipitation and anti-ARNT, anti-HIF-1α and
anti-RacGAP1 antibodies for immunoblotting as indicated. (B) Western blot analysis
of inputs (left panel) and immunoprecipitates (right panel) obtained from Huh7 cells
transfected with plasmids encoding FLAG (lane 1, 3) or FLAG-MgcRacGAP (lanes 2, 4)
and subjected to hypoxia for 4 hours. Anti-HIF-1α antibody was used for immunopre-
cipitation and anti-ARNT, anti-HIF-1α and anti-FLAG antibodies for immunoblotting, as
indicated.
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teraction, we assayed the impact of MgcRacGAP overexpression on
HIF-2 transcriptional activity. HEK293T cells were transfected with
pEGFP-HIF-2α in the presence or absence of pFLAG-MgcRacGAP and
HRE-driven luciferase activity was measured. As shown in the left
panel of Fig. 6A, HIF-2 transcriptional activity was not affected by
MgcRacGAP co-expression, whereas the inhibitory effect ofMgcRacGAP
on HIF-1 transcriptional activity was once again evident, although
expression levels of GFP-HIF-1, GFP-HIF-2 andMgcRacGAPwere practi-
cally unaffected by the conditions used (Fig. 6A, right panel). We sub-
sequently measured endogenous HIF-2 activity in the presence of
MgcRacGAP under hypoxia. Since both HIF-1α and HIF-2α are ex-
pressed in these cells, we used native promoter-driven luciferase
reporter plasmids (pGL3-PGK and pGL3-Sod2), in order to simulta-
neously and separately monitor for transcriptional activity of the two
molecules. The two reporter plasmids have been shown to be speciﬁcal-
ly activated by either HIF-1 (pGL3-PGK) or HIF-2 (pGL3-Sod2) [35,36]
and this is also evident in Huh7 cells under our experimental conditions
(Befani et al., manuscript submitted). Huh7 cells were transfected
with pFLAG-MgcRacGAP or pFLAG-ARNT or both, in the presence of
either pGL3-PGK or pGL3-Sod2 and subjected to hypoxia. Presented inFig. 6B, our results show a clear difference of the inﬂuence of
MgcRacGAP on HIF-1 or HIF-2 transcriptional activity: Whereas HIF-1
activity is shown to be repressed in the presence of MgcRacGAP and re-
cover by the addition of ARNT (left panel), HIF-2 activity remains unaf-
fected (right panel). The above results suggest that MgcRacGAP does
not bind on the HIF-2α PAS-B domain, structurally and functionally
distinguishing between the two HIF isoforms.
4. Discussion
HIF-1 is today one of the most intensively explored molecules, be-
cause of its importance in development and its major role in diseases
such as ischemia and cancer.
In fact, research for novel, HIF speciﬁc inhibitors, is highly intense
[13,14].
We have shown previously that MgcRacGAP inhibits HIF-1 activity
by binding to the inducible subunit of HIF-1, HIF-1α. Repression of
HIF-1 transcriptional activity is not due to altered HIF-1α protein
levels or subcellular localization [15]. Binding of MgcRacGAP to
HIF-1α is mediated through its Myo domain, a coiled-coil domain re-
sembling myosins and mainly tropomyosins [18]. In this work we
have explored the mechanism of MgcRacGAP-mediated HIF-1 activity
inhibition. We present evidence that the above phenomenon is due to
the competition of MgcRacGAP with ARNT for binding to the PAS-B
domain of HIF-1α, diminishing, thus, the effective HIF-1α-ARNT
dimer concentration and inhibiting HIF-1 transcriptional efﬁciency.
We ﬁrst show that the catalytic activity of MgcRacGAP is not re-
quired for MgcRacGAP-mediated repression and that the Myo domain
of MgcRacGAP is not only necessary [15] but also sufﬁcient for the
transcriptional inactivation of HIF-1. This observation suggests that
the other domains of MgcRacGAP are not required for its effect on
HIF-1 activity, implying that direct binding of the Myo domain on
HIF-1α is sufﬁcient for HIF-1 activity inhibition, without intervention
from other molecules. We further establish that the Myo domain
binds speciﬁcally to the PAS-B domain contained in the HIF-1α
fragment that was initially used to detect the interaction with
MgcRacGAP. Since PAS-B is required for the heterodimerization of
HIF-1α with ARNT, this ﬁnding supports the MgcRacGAP-ARNT com-
petition hypothesis. Accordingly, overexpression of ARNT in mamma-
lian cells alleviates the MgcRacGAP-mediated repression of HIF-1
activity. We have conﬁrmed the competition between MgcRacGAP
and ARNT for HIF-1α binding by in vitro pull down experiments and
we have further conﬁrmed by co-immunoprecipitation experiments
that overexpression of MgcRacGAP in cultured cells displaces ARNT
from HIF-1 dimers in vivo. We additionally show that the effect of
MgcRacGAP on HIF-1 transcriptional activity is not exerted on HIF-2,
underscoring the speciﬁcity of the MgcRacGAP binding on HIF-1α
and functionally differentiating between HIF-1 and HIF-2.
Regulation of transcription factor activity by differential dimeriza-
tion is not an uncommon mechanism. Several proteins act as inhibitors
of transcription factor activity by binding and replacing a functional
subunit of the transcription factor complex. Proteins escorting or
retaining transcription factors at speciﬁc loci into the cell are also
known regulators of transcription factor activity. In fact, regulation of
HIF-1 activity by control of its dimerization is a mechanism already
shown to be used by the cell: Hsp90 competes with ARNT for HIF-1α
binding [37], casein kinase 1 (CK1) phosphorylates a Ser at the PAS-B
domain inhibiting dimerization [38], ARNT interacting peptide
(Ainp1) binds on the PAS-B domain of ARNT similarly reducing the
HIF-1 dimers [39] and septin9_i1 binds on the bHLH domain of
HIF-1α, stabilizing the dimer [40].
Dimerization of HIF-1α with ARNT is a prerequisite for DNA bind-
ing and subsequent transcriptional activation by HIF-1 [41]. The
PAS-B domain core motif folds in a tertiary structure containing a
β-sheet ﬂanked on one face by a-helices. Studies on the structural re-
quirements for HIF-2α-ARNT PAS-B domain heterodimerization show
Fig. 6.MgcRacGAP overexpression does not affect HIF-2 transcriptional activity. (A) HIF-1 and HIF-2 transcriptional activity was determined 24 hours after transfection (left panel).
HEK293T cells were transfected with plasmids expressing the indicated proteins. Expression levels of FLAG-MgcRacGAP (lanes 2, 4), GFP-HIF-1α (lanes 1, 2), and GFP-HIF-2α (lanes
3, 4), were monitored by Western blot analysis with the indicated antibodies (right panel). Values are presented as the ratio of ﬁreﬂy over renilla luciferase activity divided by the
value obtained by cells transfected only with the empty vectors. Results represent the mean of two independent experiments performed in triplicates (±S.E.). (B) HIF-1 (left panel)
and HIF-2 (right panel) transcriptional activity was determined 24 hours after transfection of Huh7 cells with plasmids expressing the indicated proteins and the pGL3-PGK and
pGL3-Sod2 reporter plasmids respectively. Incubation under hypoxia was for 4 hours. Values are presented as a ratio of ﬁreﬂy over renilla luciferase activity divided by the
value obtained from cells transfected with the empty vector and maintained in normoxia. Results represent the mean of two independent experiments performed in triplicates
(±S.E.). Statistical comparisons between two groups of data are indicated with horizontal lines. Asterisk denotes statistical signiﬁcance. Only values p b 0.05 are considered signif-
icant (*p b 0.05; **p b 0.01; ***p b 0.001). Only signiﬁcant comparisons are indicated.
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solvent exposed surface of their central β-sheets [42]. The central
sheets Hβ and Iβ are located at the C-terminal part of the PAS-B re-
gion and mutagenesis of speciﬁc residues in this region abolishes di-
merization. The HIF-1α PAS-B domain is suggested to use the same
interphase as HIF-2 and the samemodules are also used for the weak-
er ARNT homodimerization [43].
We have recently reported that when Ser247, located at the Aβ
strand of PAS-B HIF-1α, is phosphorylated by CK1, dimerization is
impaired, as well as HIF-1 transcriptional activity [38]. Our exper-
iments with S247A HIF-1α (no phosphorylation) and S247D HIF-1α
(phosphorylation mimicking) suggest that MgcRacGAP-mediated inhi-
bition of HIF-1 activity is not affected by phosphorylation since bothmu-
tants show lower transcriptional activity in the presence of MgcRacGAP,
similar to the wild typemolecule (data not shown). Recently, a new role
of the PAS-B domain of bHLH-PAS transcription factors has emerged, in
regulating coactivator recruitment and oligomerization status. It was
shown that coactivators bearing α-helices and especially coiled-coil
domains bind to the α-helical part of the PAS-B domain without
compromising interactions mediated by the β-sheet [44]. In fact, the
transcriptional coactivator TACC3 of HIF-1 binds to the PAS-B domain
of ARNT and enhances HIF-1 transcriptional activity [45].
The fragment of HIF-1α thatwe have used in our in vitro binding ex-
periments (aminoacids 240–353) contains the whole PAS-B domain
and was shown to bind MgcRacGAP speciﬁcally and with practicallyequal efﬁciency as the HisGFP-HIF-1α(244–532) fragment. We do not
know at present which region of the PAS-B domain is involved in
MgcRacGAP binding. However, our results suggest that MgcRacGAP
binds on the β-sheet part of the HIF-1α PAS-B domain rather than the
a-helix, since it displaces ARNT. Supporting this, we found aweak bind-
ing of MgcRacGAP on the fragment containing only the central β-sheet
strand Iβ (critical for PAS-B domain dimerization) (Fig. 2A). Moreover,
since the phosphorylation at the Aβ strand does not disturb the
MgcRacGAP effect on HIF-1 activity, this β-strand is probably not part
of the MgcRacGAP-HIF-1α interaction surface.
It is very interesting that although the PAS-B domains of HIF-1α
and HIF-2α are highly conserved, MgcRacGAP does not bind to
HIF-2α as suggested by our transcriptional activity studies. Accord-
ingly, and contrary to HIF-1, the activity of HIF-2 was unaffected by
MgcRacGAP when expressed endogenously under hypoxia, as moni-
tored by HIF-1 and HIF-2-speciﬁc reporter plasmids. The speciﬁc
binding of MgcRacGAP on the PAS-B domain of HIF-1α and not that
of HIF-2α suggests that the interaction relies on HIF-1α-speciﬁc resi-
dues and not simply on residues deﬁning the general features of
PAS-B domains. Deletion and site-speciﬁc mutagenesis studies will
identify the residues involved in the speciﬁc HIF-1α-MgcRacGAP
interaction.
Given that the interaction of MgcRacGAP with HIF-1α disturbs
HIF-1α-ARNT dimerization, its action should liberate monomeric
HIF-1α and ARNT molecules that would otherwise be complexed
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as Max or Sp1 via the PAS-B domain in ARNT-free complexes [46,47]
frequently resulting in repression of gene expression under hypoxia.
On the other hand, ARNT has many different partners that implicate it
in several different cellular control pathways. It has even been shown
to be redistributed between the cytoplasm and the nucleus under
the effect of Ainp1, a peptide that binds on its PAS-B domain [39]. It is
possible that monomeric ARNT molecules that would otherwise be
bound to HIF-1α, in the presence of MgcRacGAP bind to other mole-
cules such as HIF-2α or AhR, or homodimerize, depending on the rela-
tive concentration of the different peptides and the status of the cell.
This way, MgcRacGAP interference might simultaneously diminish
HIF-1 activity and affect the action of another ARNT-binding molecule.
It would thus be interesting to monitor the activity of ARNT dependent
pathways in the presence of MgcRacGAP.
It is not clear in the case of the MgcRacGAP mediated HIF-1 inhibi-
tion if this is a novel function of MgcRacGAP or an action that is
connected with one of the functions of MgcRacGAP in cytoskeletal
organization. It is interesting that another protein functioning in
cytoskeletal organization, a septin, has been recently shown to bind
to HIF-1α (but not HIF-2α) and regulate its activity. Septins are
evolutionary conserved GTP-binding cytoskeletal proteins that form
ﬁlaments associated with cytoskeleton organization, membrane dy-
namics, mitosis, cytokinesis and cell cycle progression [48,49]. They
play an important role in cytokinesis by rigidifying the cleavage
furrow but they are also shown to scaffold, anchor or stabilize other
proteins [50,51]. Septin9_i1 binds to the bHLH domain of HIF-1α
and prevents its degradation by displacing RACK1. RACK1 binds on
the PAS-A domain and competes with the stabilizing protein HSP90
promoting thus the degradation of HIF-1α at the proteasome, in an
oxygen-independent regulatory mechanism [40,52]. The binding of
Sept9_i1 on HIF-1α also stabilizes the HIF-1α-ARNT complex, further
increasing HIF-1 activity. Septins have been shown to be upregulated
in cancer cells and Sept9_iv knock out in prostate cells reduces cellular
proliferation, tumor growth and angiogenesis in a HIF-1 dependent
manner. Hence, both proteins (Septin9_i1 and MgcRacGAP) can bind
on the bHLH-PAS domain of HIF-1α and modulate its dimerization
with ARNT either positively (Septin9_i1) or negatively (MgcRacGAP).
A cross-talk between signaling pathways regulating cytoskeletal
organization and the hypoxia response has already been document-
ed: Hypoxia can induce alterations to cytoskeletal structures and
Rho protein function has been implicated in hypoxia induced cyto-
skeletal changes. Furthermore, Rac1 has been shown to be activated
during hypoxia and also to be required for HIF-1 activation [53–57].
The inhibition of HIF-1 by the inhibitor of Rac1 activity, MgcRacGAP,
could be part of this cross-talk, functioning for the down-regulation
of HIF-1 activity either via Rac1, or directly, by binding to HIF-1α. A
recent study showing involvement of MgcRacGAP in v-Src oncogene
induced transformation suggests that the virus induces constitutive
(during all the phases of the cell cycle) phosphorylation at Ser387
in the catalytic domain, inactivating its Rac1 directed activity,
resulting in active Rac1 which is required for v-Src induced oncogenic
transformation [24,58].
Why and when MgcRacGAP, a cytoskeleton function regulator, in-
hibits HIF-1 activity in vivo under physiological conditions, remains to
be explored. MgcRacGAP expression has been shown to be cell-cycle
regulated [59] and this property could be important for HIF-1 activity
or compartmentalization in the cell under physiological conditions,
and most importantly, under tumoral growth conditions. HIF-1 has
been shown to affect, except from growth and metabolic regulation
of cancer cells, epithelial to mesenchymal transition, invasion and
metastasis [13], processes involving cell differentiation and motility,
evidently requiring a ﬁne-tuned cross-talk between hypoxia and
cytoskeleton function. Our results suggest that peptides derived from
the region of the MgcRacGAP Myo domain that binds to HIF-1α could
be exploited as selective inhibitors of HIF-1 activity.In conclusion, we have delineated the principles of the mechanism
by which MgcRacGAP inhibits HIF-1 activity. Further exploration of
the MgcRacGAPmediated inhibition of HIF-1 will provide precious in-
formation on basic processes of the cell such as the hypoxia response
and cytoskeleton function, but also tools for pharmaceutical interven-
tion on HIF-1 function.
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